GC1008
GC1008 is a pan-neutralizing IgG4 human antibody directed against all three isoforms of Transforming Growth Factor β (TGFβ).
TGFβ is implicated in the progression of late-stage tumors via a number of different mechanisms, of which the most notable is downregulation of the ability of the patient to mount an immune response to the tumor. In preclinical research studies TGFβ has been shown to upregulate the production of regulatory T cells and downregulate the responsiveness of cytotoxic T lymphocytes, leading to compromised immune capability. Metastatic melanoma and renal cell carcinoma (RCC) are being investigated as possible targets for anti-TGFβ therapy as both are known to be immunogenic cancers.
GC1008 is currently being studied in a Phase I/II dose-escalation study in patients with advanced metastatic melanoma or renal cell carcinoma (RCC).
GC1008 is also being investigated for focal segmental glomerulosclerosis (FSGS) and idiopathic pulmonary fibrosis (IPF).